1. Home
  2. ATRC

as of 03-03-2026 1:06pm EST

$31.38
+$0.45
+1.45%
Stocks Health Care Medical/Dental Instruments Nasdaq

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Founded: 2000 Country:
United States
United States
Employees: N/A City: MASON
Market Cap: 1.8B IPO Year: 2005
Target Price: $51.17 AVG Volume (30 days): 811.4K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.24 EPS Growth: 74.74
52 Week Low/High: $28.32 - $43.18 Next Earning Date: 05-11-2026
Revenue: $201,630,000 Revenue Growth: 15.40%
Revenue Growth (this year): 14.9% Revenue Growth (next year): 12.87%
P/E Ratio: -128.29 Index: N/A
Free Cash Flow: 48.3M FCF Growth: +6381.07%

AI-Powered ATRC Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 19 hours ago

AI Recommendation

hold
Model Accuracy: 76.73%
76.73%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest AtriCure Inc. News

ATRC Breaking Stock News: Dive into ATRC Ticker-Specific Updates for Smart Investing

All ATRC News

Share on Social Networks: